Loading…
ProMIS Neurosciences Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.0% over 5Y.
today you would have $53.67▼ -94.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $6.83 | $23.75 | $28.75 | $108.50 | $165.00 | |
| P/E | — | — | 9.0x | — | — | — |
| P/B | 5.8x | — | 1.9x | 5.8x | — | 8.4x |
| EPS | -$22.61 | $2.63 | -$26.75 | -$60.25 | -$42.25 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ENGNenGene Therapeutics Inc. | $1.83 | — | 0.5x | — | -52.59% | $122.26M |
| BMEABiomea Fusion, Inc. | $1.73 | — | 10.4x | — | -164.14% | $125.08M |
| NTHINeonc Technologies Holdings Inc | $4.69 | — | — | — | — | $121.64M |
| CBUSCibus, Inc. | $1.65 |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Company description provided by Yahoo Finance.
| ROE | -172.97% | — | 16.85% | -352.02% | — | -172.97% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 8.5x |
| — |
| -223.16% |
| $126.11M |
| AARDAardvark Therapeutics, Inc. | $5.79 | — | 1.7x | — | -66.02% | $126.71M |
| CPIXCumberland Pharmaceuticals Inc | $8.46 | — | 7.3x | — | -14.39% | $126.76M |